Clinical trial / 2009
Higher green tea extract doses improved response rates in oral premalignant lesions.
Patients with high-risk oral premalignant lesions received green tea extract (500, 750, or 1,000 mg/m2) or placebo three times daily for 12 weeks. Clinical response was 50% across extract groups (n = 28) versus 18.2% for placebo (n = 11; P = 0.09), but reached 58.8% in the two highest-dose groups combined (P = 0.03). Histologic improvement was not significantly different (P = 0.65), and while higher doses increased insomnia and nervousness, no grade 4 toxicities were seen.
- Study type
- Randomized placebo-controlled trial
- Who was studied
- 39 patients with high-risk oral premalignant lesions
- What was measured
- Clinical and histologic response of oral premalignant lesions
THE PAPER
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.
Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Cancer Prev Res (Phila), 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.